Analyst Says Citron Note Creates Buying Opportunity in VIVUS (VVUS)
Tweet Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $14.82 +2.21%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade VVUS Now!
Rodman & Renshaw's Michael King is recommending investors buy the dip in shares of VIVUS (Nasdaq: VVUS) following a negative report from the infamous Citron Research. The stock fell by more than 11 percent on Thursday.
King reassured VIVUS's Qsymia is protected by the issued patents. He noted the tone of the Citron note was intended to create uncertainty and doubt related to the company and its stock.
King reiterated a Market Outperform rating and $52 price target on shares of VIVUS.
With VIVUS shares down 0.7 percent to $25.60 in Friday's pre-open session, King's price target represents potential upside of more than 100 percent.
Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of VIVUS.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
King reassured VIVUS's Qsymia is protected by the issued patents. He noted the tone of the Citron note was intended to create uncertainty and doubt related to the company and its stock.
King reiterated a Market Outperform rating and $52 price target on shares of VIVUS.
With VIVUS shares down 0.7 percent to $25.60 in Friday's pre-open session, King's price target represents potential upside of more than 100 percent.
Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of VIVUS.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sarissa Capital Shows New 1.99% Stake in Vivus, Inc. (VVUS), Denner Nominated to Board
- Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
- Wedbush Downgrades salesforce.com (CRM) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Rodman & Renshaw, Citron Research
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
